Global Neurodegenerative Disorder Therapeutics Market Insights, Forecast to 2029
This report presents an overview of global market for Neurodegenerative Disorder Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Neurodegenerative Disorder Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neurodegenerative Disorder Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neurodegenerative Disorder Therapeutics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Neurodegenerative Disorder Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Neurodegenerative Disorder Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck and Merck KGaA, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Neurodegenerative Disorder Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disorder Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disorder Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Neurodegenerative Disorder Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neurodegenerative Disorder Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neurodegenerative Disorder Therapeutics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Neurodegenerative Disorder Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Neurodegenerative Disorder Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Biogen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann- La Roche Ltd., H. Lundbeck and Merck KGaA, etc.
By Company
- Biogen, Inc.
- Pfizer, Inc.
- Novartis AG
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- F. Hoffmann- La Roche Ltd.
- H. Lundbeck
- Merck KGaA
- GlaxoSmithKline PLC
- AbbVie Inc.
- Bristol Myers Squibb Company
- Boehringer Ingeiheim International GmbH
- Bayer AG
- Eisai Co., Ltd
- Immunomodulators
- Interferons
- Decarboxylase Inhibitors
- Dopamine Agonists
- Others
- Multiple Sclerosis
- Parkinson'S Disease
- Alzheimer'S Disease
- Spinal Muscular Atrophy
- Huntington Disease
- Other Neurodegenerative Disorders
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Neurodegenerative Disorder Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disorder Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disorder Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Immunomodulators
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Multiple Sclerosis
1.3.3 Parkinson'S Disease
1.3.4 Alzheimer'S Disease
1.3.5 Spinal Muscular Atrophy
1.3.6 Huntington Disease
1.3.7 Other Neurodegenerative Disorders
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2018-2029)
2.2 Global Neurodegenerative Disorder Therapeutics Growth Trends by Region
2.2.1 Neurodegenerative Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Neurodegenerative Disorder Therapeutics Market Dynamics
2.3.1 Neurodegenerative Disorder Therapeutics Industry Trends
2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers
2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges
2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Neurodegenerative Disorder Therapeutics by Players
3.1.1 Global Neurodegenerative Disorder Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Neurodegenerative Disorder Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2022
3.5 Global Key Players of Neurodegenerative Disorder Therapeutics Head office and Area Served
3.6 Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application
3.7 Global Key Players of Neurodegenerative Disorder Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 NEURODEGENERATIVE DISORDER THERAPEUTICS BREAKDOWN DATA BY TYPE
4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2024-2029)
5 NEURODEGENERATIVE DISORDER THERAPEUTICS BREAKDOWN DATA BY APPLICATION
5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
6.2 North America Neurodegenerative Disorder Therapeutics Market Size by Type
6.2.1 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
6.2.2 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
6.2.3 North America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Application
6.3.1 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
6.3.2 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
6.3.3 North America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country
6.4.1 North America Neurodegenerative Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
6.4.3 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 EUROPE
7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
7.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type
7.2.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
7.2.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
7.2.3 Europe Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Application
7.3.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
7.3.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
7.3.3 Europe Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country
7.4.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
7.4.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
8.2 China Neurodegenerative Disorder Therapeutics Market Size by Type
8.2.1 China Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
8.2.2 China Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
8.2.3 China Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
8.3 China Neurodegenerative Disorder Therapeutics Market Size by Application
8.3.1 China Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
8.3.2 China Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
8.3.3 China Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
9.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Type
9.2.1 Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
9.2.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
9.2.3 Asia Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
9.3 Asia Neurodegenerative Disorder Therapeutics Market Size by Application
9.3.1 Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
9.3.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
9.3.3 Asia Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
9.4 Asia Neurodegenerative Disorder Therapeutics Market Size by Region
9.4.1 Asia Neurodegenerative Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023)
9.4.3 Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Biogen, Inc.
11.1.1 Biogen, Inc. Company Details
11.1.2 Biogen, Inc. Business Overview
11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.1.5 Biogen, Inc. Recent Developments
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Details
11.2.2 Pfizer, Inc. Business Overview
11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.2.5 Pfizer, Inc. Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction
11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.3.5 Novartis AG Recent Developments
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Details
11.4.2 Sanofi S.A. Business Overview
11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction
11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.4.5 Sanofi S.A. Recent Developments
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.6 UCB S.A.
11.6.1 UCB S.A. Company Details
11.6.2 UCB S.A. Business Overview
11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction
11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.6.5 UCB S.A. Recent Developments
11.7 F. Hoffmann- La Roche Ltd.
11.7.1 F. Hoffmann- La Roche Ltd. Company Details
11.7.2 F. Hoffmann- La Roche Ltd. Business Overview
11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.7.5 F. Hoffmann- La Roche Ltd. Recent Developments
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Details
11.8.2 H. Lundbeck Business Overview
11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction
11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.8.5 H. Lundbeck Recent Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Details
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction
11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.9.5 Merck KGaA Recent Developments
11.10 GlaxoSmithKline PLC
11.10.1 GlaxoSmithKline PLC Company Details
11.10.2 GlaxoSmithKline PLC Business Overview
11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction
11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.10.5 GlaxoSmithKline PLC Recent Developments
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Details
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction
11.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.11.5 AbbVie Inc. Recent Developments
11.12 Bristol Myers Squibb Company
11.12.1 Bristol Myers Squibb Company Company Details
11.12.2 Bristol Myers Squibb Company Business Overview
11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction
11.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.12.5 Bristol Myers Squibb Company Recent Developments
11.13 Boehringer Ingeiheim International GmbH
11.13.1 Boehringer Ingeiheim International GmbH Company Details
11.13.2 Boehringer Ingeiheim International GmbH Business Overview
11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction
11.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.13.5 Boehringer Ingeiheim International GmbH Recent Developments
11.14 Bayer AG
11.14.1 Bayer AG Company Details
11.14.2 Bayer AG Business Overview
11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction
11.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.14.5 Bayer AG Recent Developments
11.15 Eisai Co., Ltd
11.15.1 Eisai Co., Ltd Company Details
11.15.2 Eisai Co., Ltd Business Overview
11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction
11.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.15.5 Eisai Co., Ltd Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Immunomodulators
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Multiple Sclerosis
1.3.3 Parkinson'S Disease
1.3.4 Alzheimer'S Disease
1.3.5 Spinal Muscular Atrophy
1.3.6 Huntington Disease
1.3.7 Other Neurodegenerative Disorders
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2018-2029)
2.2 Global Neurodegenerative Disorder Therapeutics Growth Trends by Region
2.2.1 Neurodegenerative Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Neurodegenerative Disorder Therapeutics Market Dynamics
2.3.1 Neurodegenerative Disorder Therapeutics Industry Trends
2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers
2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges
2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Neurodegenerative Disorder Therapeutics by Players
3.1.1 Global Neurodegenerative Disorder Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Neurodegenerative Disorder Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2022
3.5 Global Key Players of Neurodegenerative Disorder Therapeutics Head office and Area Served
3.6 Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application
3.7 Global Key Players of Neurodegenerative Disorder Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 NEURODEGENERATIVE DISORDER THERAPEUTICS BREAKDOWN DATA BY TYPE
4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2024-2029)
5 NEURODEGENERATIVE DISORDER THERAPEUTICS BREAKDOWN DATA BY APPLICATION
5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
6.2 North America Neurodegenerative Disorder Therapeutics Market Size by Type
6.2.1 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
6.2.2 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
6.2.3 North America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Application
6.3.1 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
6.3.2 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
6.3.3 North America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country
6.4.1 North America Neurodegenerative Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
6.4.3 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 EUROPE
7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
7.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type
7.2.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
7.2.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
7.2.3 Europe Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Application
7.3.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
7.3.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
7.3.3 Europe Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country
7.4.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
7.4.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
8.2 China Neurodegenerative Disorder Therapeutics Market Size by Type
8.2.1 China Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
8.2.2 China Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
8.2.3 China Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
8.3 China Neurodegenerative Disorder Therapeutics Market Size by Application
8.3.1 China Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
8.3.2 China Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
8.3.3 China Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
9.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Type
9.2.1 Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
9.2.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
9.2.3 Asia Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
9.3 Asia Neurodegenerative Disorder Therapeutics Market Size by Application
9.3.1 Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
9.3.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
9.3.3 Asia Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
9.4 Asia Neurodegenerative Disorder Therapeutics Market Size by Region
9.4.1 Asia Neurodegenerative Disorder Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023)
9.4.3 Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Biogen, Inc.
11.1.1 Biogen, Inc. Company Details
11.1.2 Biogen, Inc. Business Overview
11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.1.5 Biogen, Inc. Recent Developments
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Details
11.2.2 Pfizer, Inc. Business Overview
11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.2.5 Pfizer, Inc. Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction
11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.3.5 Novartis AG Recent Developments
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Details
11.4.2 Sanofi S.A. Business Overview
11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction
11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.4.5 Sanofi S.A. Recent Developments
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.6 UCB S.A.
11.6.1 UCB S.A. Company Details
11.6.2 UCB S.A. Business Overview
11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction
11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.6.5 UCB S.A. Recent Developments
11.7 F. Hoffmann- La Roche Ltd.
11.7.1 F. Hoffmann- La Roche Ltd. Company Details
11.7.2 F. Hoffmann- La Roche Ltd. Business Overview
11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.7.5 F. Hoffmann- La Roche Ltd. Recent Developments
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Details
11.8.2 H. Lundbeck Business Overview
11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction
11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.8.5 H. Lundbeck Recent Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Details
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction
11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.9.5 Merck KGaA Recent Developments
11.10 GlaxoSmithKline PLC
11.10.1 GlaxoSmithKline PLC Company Details
11.10.2 GlaxoSmithKline PLC Business Overview
11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction
11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.10.5 GlaxoSmithKline PLC Recent Developments
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Details
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction
11.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.11.5 AbbVie Inc. Recent Developments
11.12 Bristol Myers Squibb Company
11.12.1 Bristol Myers Squibb Company Company Details
11.12.2 Bristol Myers Squibb Company Business Overview
11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction
11.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.12.5 Bristol Myers Squibb Company Recent Developments
11.13 Boehringer Ingeiheim International GmbH
11.13.1 Boehringer Ingeiheim International GmbH Company Details
11.13.2 Boehringer Ingeiheim International GmbH Business Overview
11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction
11.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.13.5 Boehringer Ingeiheim International GmbH Recent Developments
11.14 Bayer AG
11.14.1 Bayer AG Company Details
11.14.2 Bayer AG Business Overview
11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction
11.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.14.5 Bayer AG Recent Developments
11.15 Eisai Co., Ltd
11.15.1 Eisai Co., Ltd Company Details
11.15.2 Eisai Co., Ltd Business Overview
11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction
11.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.15.5 Eisai Co., Ltd Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Immunomodulators
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 8. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2018-2023)
Table 11. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2024-2029)
Table 13. Neurodegenerative Disorder Therapeutics Market Trends
Table 14. Neurodegenerative Disorder Therapeutics Market Drivers
Table 15. Neurodegenerative Disorder Therapeutics Market Challenges
Table 16. Neurodegenerative Disorder Therapeutics Market Restraints
Table 17. Global Neurodegenerative Disorder Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Neurodegenerative Disorder Therapeutics Revenue Share by Players (2018-2023)
Table 19. Global Top Neurodegenerative Disorder Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2022)
Table 20. Global Neurodegenerative Disorder Therapeutics Industry Ranking 2021 VS 2022 VS 2023
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Disorder Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 22. Global Key Players of Neurodegenerative Disorder Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application
Table 24. Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2018-2023)
Table 28. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2024-2029)
Table 30. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Neurodegenerative Disorder Therapeutics Revenue Share by Application (2018-2023)
Table 32. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Neurodegenerative Disorder Therapeutics Revenue Share by Application (2024-2029)
Table 34. North America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 35. North America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 36. North America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 37. North America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 38. North America Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 40. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 41. Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 42. Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 43. Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 44. Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 45. Europe Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 47. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 48. China Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 49. China Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 50. China Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 51. China Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 52. Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 53. Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 54. Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 55. Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 56. Asia Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 58. Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 64. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 66. Biogen, Inc. Company Details
Table 67. Biogen, Inc. Business Overview
Table 68. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product
Table 69. Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 70. Biogen, Inc. Recent Developments
Table 71. Pfizer, Inc. Company Details
Table 72. Pfizer, Inc. Business Overview
Table 73. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product
Table 74. Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 75. Pfizer, Inc. Recent Developments
Table 76. Novartis AG Company Details
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Neurodegenerative Disorder Therapeutics Product
Table 79. Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Novartis AG Recent Developments
Table 81. Sanofi S.A. Company Details
Table 82. Sanofi S.A. Business Overview
Table 83. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product
Table 84. Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Sanofi S.A. Recent Developments
Table 86. Teva Pharmaceutical Industries Ltd. Company Details
Table 87. Teva Pharmaceutical Industries Ltd. Business Overview
Table 88. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product
Table 89. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 91. UCB S.A. Company Details
Table 92. UCB S.A. Business Overview
Table 93. UCB S.A. Neurodegenerative Disorder Therapeutics Product
Table 94. UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 95. UCB S.A. Recent Developments
Table 96. F. Hoffmann- La Roche Ltd. Company Details
Table 97. F. Hoffmann- La Roche Ltd. Business Overview
Table 98. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product
Table 99. F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 100. F. Hoffmann- La Roche Ltd. Recent Developments
Table 101. H. Lundbeck Company Details
Table 102. H. Lundbeck Business Overview
Table 103. H. Lundbeck Neurodegenerative Disorder Therapeutics Product
Table 104. H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 105. H. Lundbeck Recent Developments
Table 106. Merck KGaA Company Details
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Neurodegenerative Disorder Therapeutics Product
Table 109. Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 110. Merck KGaA Recent Developments
Table 111. GlaxoSmithKline PLC Company Details
Table 112. GlaxoSmithKline PLC Business Overview
Table 113. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product
Table 114. GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 115. GlaxoSmithKline PLC Recent Developments
Table 116. AbbVie Inc. Company Details
Table 117. AbbVie Inc. Business Overview
Table 118. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product
Table 119. AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 120. AbbVie Inc. Recent Developments
Table 121. Bristol Myers Squibb Company Company Details
Table 122. Bristol Myers Squibb Company Business Overview
Table 123. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product
Table 124. Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 125. Bristol Myers Squibb Company Recent Developments
Table 126. Boehringer Ingeiheim International GmbH Company Details
Table 127. Boehringer Ingeiheim International GmbH Business Overview
Table 128. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product
Table 129. Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 130. Boehringer Ingeiheim International GmbH Recent Developments
Table 131. Bayer AG Company Details
Table 132. Bayer AG Business Overview
Table 133. Bayer AG Neurodegenerative Disorder Therapeutics Product
Table 134. Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 135. Bayer AG Recent Developments
Table 136. Eisai Co., Ltd Company Details
Table 137. Eisai Co., Ltd Business Overview
Table 138. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product
Table 139. Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 140. Eisai Co., Ltd Recent Developments
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
Table 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Immunomodulators
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 8. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2018-2023)
Table 11. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2024-2029)
Table 13. Neurodegenerative Disorder Therapeutics Market Trends
Table 14. Neurodegenerative Disorder Therapeutics Market Drivers
Table 15. Neurodegenerative Disorder Therapeutics Market Challenges
Table 16. Neurodegenerative Disorder Therapeutics Market Restraints
Table 17. Global Neurodegenerative Disorder Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Neurodegenerative Disorder Therapeutics Revenue Share by Players (2018-2023)
Table 19. Global Top Neurodegenerative Disorder Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2022)
Table 20. Global Neurodegenerative Disorder Therapeutics Industry Ranking 2021 VS 2022 VS 2023
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Disorder Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 22. Global Key Players of Neurodegenerative Disorder Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application
Table 24. Global Key Players of Neurodegenerative Disorder Therapeutics, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2018-2023)
Table 28. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2024-2029)
Table 30. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Neurodegenerative Disorder Therapeutics Revenue Share by Application (2018-2023)
Table 32. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Neurodegenerative Disorder Therapeutics Revenue Share by Application (2024-2029)
Table 34. North America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 35. North America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 36. North America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 37. North America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 38. North America Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 40. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 41. Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 42. Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 43. Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 44. Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 45. Europe Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 47. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 48. China Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 49. China Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 50. China Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 51. China Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 52. Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 53. Asia Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 54. Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 55. Asia Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 56. Asia Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 58. Asia Neurodegenerative Disorder Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2024-2029) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 64. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 66. Biogen, Inc. Company Details
Table 67. Biogen, Inc. Business Overview
Table 68. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product
Table 69. Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 70. Biogen, Inc. Recent Developments
Table 71. Pfizer, Inc. Company Details
Table 72. Pfizer, Inc. Business Overview
Table 73. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product
Table 74. Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 75. Pfizer, Inc. Recent Developments
Table 76. Novartis AG Company Details
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Neurodegenerative Disorder Therapeutics Product
Table 79. Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Novartis AG Recent Developments
Table 81. Sanofi S.A. Company Details
Table 82. Sanofi S.A. Business Overview
Table 83. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product
Table 84. Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Sanofi S.A. Recent Developments
Table 86. Teva Pharmaceutical Industries Ltd. Company Details
Table 87. Teva Pharmaceutical Industries Ltd. Business Overview
Table 88. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product
Table 89. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 91. UCB S.A. Company Details
Table 92. UCB S.A. Business Overview
Table 93. UCB S.A. Neurodegenerative Disorder Therapeutics Product
Table 94. UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 95. UCB S.A. Recent Developments
Table 96. F. Hoffmann- La Roche Ltd. Company Details
Table 97. F. Hoffmann- La Roche Ltd. Business Overview
Table 98. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product
Table 99. F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 100. F. Hoffmann- La Roche Ltd. Recent Developments
Table 101. H. Lundbeck Company Details
Table 102. H. Lundbeck Business Overview
Table 103. H. Lundbeck Neurodegenerative Disorder Therapeutics Product
Table 104. H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 105. H. Lundbeck Recent Developments
Table 106. Merck KGaA Company Details
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Neurodegenerative Disorder Therapeutics Product
Table 109. Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 110. Merck KGaA Recent Developments
Table 111. GlaxoSmithKline PLC Company Details
Table 112. GlaxoSmithKline PLC Business Overview
Table 113. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product
Table 114. GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 115. GlaxoSmithKline PLC Recent Developments
Table 116. AbbVie Inc. Company Details
Table 117. AbbVie Inc. Business Overview
Table 118. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product
Table 119. AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 120. AbbVie Inc. Recent Developments
Table 121. Bristol Myers Squibb Company Company Details
Table 122. Bristol Myers Squibb Company Business Overview
Table 123. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product
Table 124. Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 125. Bristol Myers Squibb Company Recent Developments
Table 126. Boehringer Ingeiheim International GmbH Company Details
Table 127. Boehringer Ingeiheim International GmbH Business Overview
Table 128. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product
Table 129. Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 130. Boehringer Ingeiheim International GmbH Recent Developments
Table 131. Bayer AG Company Details
Table 132. Bayer AG Business Overview
Table 133. Bayer AG Neurodegenerative Disorder Therapeutics Product
Table 134. Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 135. Bayer AG Recent Developments
Table 136. Eisai Co., Ltd Company Details
Table 137. Eisai Co., Ltd Business Overview
Table 138. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product
Table 139. Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 140. Eisai Co., Ltd Recent Developments
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Neurodegenerative Disorder Therapeutics Market Share by Type: 2022 VS 2029
Figure 3. Immunomodulators Features
Figure 4. Interferons Features
Figure 5. Decarboxylase Inhibitors Features
Figure 6. Dopamine Agonists Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2022 VS 2029
Figure 10. Multiple Sclerosis Case Studies
Figure 11. Parkinson'S Disease Case Studies
Figure 12. Alzheimer'S Disease Case Studies
Figure 13. Spinal Muscular Atrophy Case Studies
Figure 14. Huntington Disease Case Studies
Figure 15. Other Neurodegenerative Disorders Case Studies
Figure 16. Neurodegenerative Disorder Therapeutics Report Years Considered
Figure 17. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 18. Global Neurodegenerative Disorder Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 19. Global Neurodegenerative Disorder Therapeutics Market Share by Region: 2022 VS 2029
Figure 20. Global Neurodegenerative Disorder Therapeutics Market Share by Players in 2022
Figure 21. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2022
Figure 23. North America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 25. North America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 26. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2029)
Figure 27. United States Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 30. Europe Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 31. Europe Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 32. Europe Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2029)
Figure 33. Germany Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. France Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. U.K. Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Italy Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Russia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Nordic Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. China Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 40. China Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 41. China Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 42. Asia Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 43. Asia Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 44. Asia Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 45. Asia Neurodegenerative Disorder Therapeutics Market Share by Region (2018-2029)
Figure 46. Japan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. South Korea Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. China Taiwan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. India Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Australia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 53. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 54. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 55. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2029)
Figure 56. Brazil Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Mexico Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Turkey Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 60. Israel Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 61. GCC Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 62. Biogen, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 63. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 64. Novartis AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 65. Sanofi S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 66. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 67. UCB S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 68. F. Hoffmann- La Roche Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 69. H. Lundbeck Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 70. Merck KGaA Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 71. GlaxoSmithKline PLC Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 72. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 73. Bristol Myers Squibb Company Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 74. Boehringer Ingeiheim International GmbH Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 75. Bayer AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 76. Eisai Co., Ltd Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
Figure 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Neurodegenerative Disorder Therapeutics Market Share by Type: 2022 VS 2029
Figure 3. Immunomodulators Features
Figure 4. Interferons Features
Figure 5. Decarboxylase Inhibitors Features
Figure 6. Dopamine Agonists Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2022 VS 2029
Figure 10. Multiple Sclerosis Case Studies
Figure 11. Parkinson'S Disease Case Studies
Figure 12. Alzheimer'S Disease Case Studies
Figure 13. Spinal Muscular Atrophy Case Studies
Figure 14. Huntington Disease Case Studies
Figure 15. Other Neurodegenerative Disorders Case Studies
Figure 16. Neurodegenerative Disorder Therapeutics Report Years Considered
Figure 17. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 18. Global Neurodegenerative Disorder Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 19. Global Neurodegenerative Disorder Therapeutics Market Share by Region: 2022 VS 2029
Figure 20. Global Neurodegenerative Disorder Therapeutics Market Share by Players in 2022
Figure 21. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2022
Figure 23. North America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 25. North America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 26. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2029)
Figure 27. United States Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 30. Europe Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 31. Europe Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 32. Europe Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2029)
Figure 33. Germany Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. France Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. U.K. Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Italy Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Russia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Nordic Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. China Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 40. China Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 41. China Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 42. Asia Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 43. Asia Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 44. Asia Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 45. Asia Neurodegenerative Disorder Therapeutics Market Share by Region (2018-2029)
Figure 46. Japan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. South Korea Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. China Taiwan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. India Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Australia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Size YoY (2018-2029) & (US$ Million)
Figure 53. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Type (2018-2029)
Figure 54. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Application (2018-2029)
Figure 55. Middle East, Africa, and Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2029)
Figure 56. Brazil Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Mexico Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Turkey Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 60. Israel Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 61. GCC Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 62. Biogen, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 63. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 64. Novartis AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 65. Sanofi S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 66. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 67. UCB S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 68. F. Hoffmann- La Roche Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 69. H. Lundbeck Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 70. Merck KGaA Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 71. GlaxoSmithKline PLC Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 72. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 73. Bristol Myers Squibb Company Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 74. Boehringer Ingeiheim International GmbH Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 75. Bayer AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 76. Eisai Co., Ltd Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
